Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Reiser

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
Leukemia & Lymphoma|November 21, 2015
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemiaDirk Müller, Kirsten Fischer, Peter Kaiser, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
International Journal of Cancer|September 2, 2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-worldNorbert Marschner, Susanna Hegewisch-Becker, Marcel Reiser, et al.
Blood|October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaHolger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
BMC Research Notes|May 15, 2024
Concepts of lines of therapy in cancer treatment: findings from an expert interview-based studyLisa Falchetto, Bernd Bender, Ian Erhard, et al.
Blood|February 17, 2012
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLCarsten Müller, Niels Murawski, Martin H J Wiesen, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Haematologica|December 18, 2012
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomasAgnieszka Korfel, Thomas Elter, Eckhard Thiel, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|November 21, 2015
Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemiaDirk Müller, Kirsten Fischer, Peter Kaiser, et al.
Leukemia & Lymphoma|September 16, 2017
Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the foreHans Tilman Steinmetz, Ulrich Germing, Annette Sauer, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
International Journal of Cancer|September 2, 2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-worldNorbert Marschner, Susanna Hegewisch-Becker, Marcel Reiser, et al.
Blood|October 18, 2002
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemiaHolger Schulz, Saskia Karina Klein, Ute Rehwald, et al.
Blood|February 26, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
BMC Research Notes|May 15, 2024
Concepts of lines of therapy in cancer treatment: findings from an expert interview-based studyLisa Falchetto, Bernd Bender, Ian Erhard, et al.
Blood|February 17, 2012
The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCLCarsten Müller, Niels Murawski, Martin H J Wiesen, et al.
Annals of Hematology|October 4, 2023
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trialSteffen Koschmieder, Susanne Isfort, Clemens Schulte, et al.
Haematologica|December 18, 2012
Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomasAgnieszka Korfel, Thomas Elter, Eckhard Thiel, et al.
Pageof 8